Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
6.88
-0.02 (-0.29%)
Dec 5, 2025, 4:00 PM EST - Market closed
Cartesian Therapeutics Stock Forecast
RNAC's stock price has decreased by -68.73% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Cartesian Therapeutics stock ranges from a low of $30 to a high of $44. The average analyst price target of $38.4 forecasts a 458.14% increase in the stock price over the next year.
Price Target: $38.40 (+458.14%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cartesian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $30 | Strong Buy | Maintains | $40 → $30 | +336.05% | Nov 19, 2025 |
| BTIG | BTIG | Strong Buy Maintains $42 → $44 | Strong Buy | Maintains | $42 → $44 | +539.53% | Nov 14, 2025 |
| Wedbush | Wedbush | Buy Initiates $38 | Buy | Initiates | $38 | +452.33% | Jul 9, 2025 |
| Needham | Needham | Strong Buy Maintains $41 → $40 | Strong Buy | Maintains | $41 → $40 | +481.40% | May 8, 2025 |
| Needham | Needham | Strong Buy Reiterates $41 | Strong Buy | Reiterates | $41 | +495.93% | Apr 9, 2025 |
Financial Forecast
Revenue This Year
2.02M
from 38.91M
Decreased by -94.81%
Revenue Next Year
686.02K
from 2.02M
Decreased by -66.06%
EPS This Year
-2.39
from -4.49
EPS Next Year
-3.44
from -2.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.4M | 2.0M | ||||
| Avg | 2.0M | 686,021 | ||||
| Low | 1.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -93.8% | -1.3% | ||||
| Avg | -94.8% | -66.1% | ||||
| Low | -95.3% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.33 | -2.75 | ||||
| Avg | -2.39 | -3.44 | ||||
| Low | -2.64 | -3.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.